기사 메일전송
TauRx Submits UK Marketing Authorisation Application for HMTM as a Treatment for Alzheimer’s Disease
  • 편집국
  • 등록 2024-07-04 00:28:23

기사수정

TauRx Pharmaceuticals Ltd, a global leader in tau-based research in Alzheimer’s disease (AD), has announced the submission of a UK Marketing Authorisation Application (MAA) for hydromethylthionine mesylate (HMTM) for treatment of mild cognitive impairment (MCI-AD) and mild to moderate stages of dementia due to Alzheimer’s disease.

HMTM has been designated by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for the Innovative Licensing and Access Pathway (ILAP). If successful, the UK could be the first country in which an accessible, safe, oral treatment, which targets the hallmark tau pathology of the disease, becomes available to patients.

The MAA is based on the totality of evidence available from the recently released 24-month Phase 3 LUCIDITY data and two earlier Phase 3 trials in mild to moderate AD. These studies have been consistent in showing benefit on measures of decline in cognition, ability to perform normal activities of daily living, and reduction in the rate of brain shrinkage.

Tau aggregation is strongly correlated with the rate and severity of cognitive decline, brain atrophy, and the damage to neurons responsible for the characteristic neurodegeneration of the disease. HMTM acts by selectively inhibiting the aggregation of tau-protein in brain nerve cells. It also has a second mode of action which results in enhancement of brain functioning.

Commenting on the submission, Professor Claude Wischik, Executive Chairman of TauRx, said: “This is a significant milestone for TauRx and is an important step in potentially bringing a new type of treatment and a new hope to patients and families who carry the burden of this terrible disease.”

NOTES

ABOUT HMTM

Hydromethylthionine mesylate (HMTM) has been developed as a potential oral treatment for AD targeting tau aggregation. It also has a secondary tau-independent mode of action which increases acetylcholine levels in the hippocampus. The global Phase 3 clinical trial LUCIDITY has recently completed and the data were presented at the AD/PD™ 2024 Alzheimer‘s & Parkinson’s Diseases Conference in Lisbon, Portugal, on 7 March. With over 3,000 subjects studied, HMTM has a strong safety profile and could be delivered with minimal patient and physician burden.

Neurofilament Light Chain (NfL) is an established biomarker for neurodegeneration. LUCIDITY showed a significant reduction in the change of NfL, in the randomised double-blind portion of the study at 12 months. Clinical measures of cognition showed improvement over baseline levels that was sustained over 18 months in MCI, as diagnosed in the LUCIDITY trial. Patients who were in the control group were unable to catch up in terms of cognitive function despite transitioning to 16mg per day HMTM (target dose) in the open-label phase after 12 months. This emphasises the importance of early intervention with effective therapies in AD.

ABOUT TAURx PHARMACEUTICALS LTD

TauRx was founded in 2002 in Singapore, with primary research facilities and operations based in Aberdeen, UK. In collaboration with the University of Aberdeen, the company has dedicated the past two decades to developing treatments and diagnostics for Alzheimer’s and other neurodegenerative diseases due to pathological aggregation of tau and other proteins.

AD is a leading cause of disability and death throughout the world and is one of the most important global public health issues. TauRx will contribute to addressing this urgent unmet need with data from the totality of evidence available from LUCIDITY and the earlier AD trials in pursuit of regulatory approvals starting in UK. TauRx’s hope is to make HMTM available for people living with Alzheimer’s as soon as possible. Future research is planned for other related neurodegenerative diseases. https://taurx.com/

View source version on businesswire.com: https://www.businesswire.com/news/home/20240701092104/en/

언론연락처: TauRx Pharmaceuticals Ltd Aspect Ruaridh Hanna 07723679101

이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.

0
  • 목록 바로가기
  • 인쇄


최신뉴스더보기
많이 본 뉴스더보기
  1. 아하 커뮤니티, 이노비즈 A등급 획득 소셜 Q&A 커뮤니티 아하를 운영 중인 아하앤컴퍼니(대표 서한울)가 중소벤처기업부로부터 이노비즈 A등급을 인증받았다고 17일 밝혔다.이노비즈는 기술 혁신 시스템 및 현장 평가를 통해 높은 기술 경쟁력과 성장 가치가 뚜렷한 기업에 부여되는 국가 인증 제도다.아하는 AI 기술을 접목한 사용자 활동 패턴 분석 시스템 등을 비롯한 다양...
  2. 하나은행, 국내 시중은행 최초 해외송금 ‘수취계좌 사전 확인’ 서비스 시행 하나은행(은행장 이승열)은 국내 시중은행 최초로 해외송금의 신뢰성과 안정성을 높이기 위해 해외 수취인 계좌 상태를 사전에 확인하고 검증할 수 있는 ‘수취계좌 사전 확인’ 서비스를 시행한다고 밝혔다.‘수취계좌 사전 확인’ 서비스 시행으로 손님이 △수취인 성명 △수취인 계좌번호 △수취은행 BIC(또는 은행코드)를 알고 하나은..
  3. 하나은행, 국제 신용평가사 피치로부터 독자신용등급 한 단계 상향된 ‘a’ 획득 하나은행(은행장 이승열)은 글로벌 3대 신용평가사 중 하나인 피치(Fitch Rating)가 하나은행의 독자신용등급을 기존 ‘a-’에서 ‘a’로 한 단계 상향했다고 밝혔다. 하나은행은 불확실한 경제 상황 속에서도 장기신용등급은 ‘A’, 등급전망은 ‘안정적’으로 유지한 가운데 독자신용등급(VR, Viability Rating)의 한 단계 상향을 이뤄내며 그간의 .
  4. 미국 부동산 플랫폼 코리니, 삼성패밀리오피스와 업무협약 체결 미국 부동산 종합 솔루션 플랫폼인 코리니(Koriny)는 삼성패밀리오피스와 전략적 업무협약(MOU)을 19일 체결했다. 패밀리오피스란 고액자산가나 기업오너 가족 등의 자산관리와 배분, 상속·증여·신탁 관련 및 더 나아가 가업승계를 전담해 관리해 주는 서비스를 말한다. 이번 업무협약을 통해 양사는 미국 부동산 투자 컨설팅을 비롯, 미국 ..
  5. 하나은행, 국제 신용평가사 피치로부터 독자신용등급 한 단계 상향된 ‘a’ 획득 하나은행(은행장 이승열)은 글로벌 3대 신용평가사 중 하나인 피치(Fitch Rating)가 하나은행의 독자신용등급을 기존 ‘a-’에서 ‘a’로 한 단계 상향했다고 밝혔다.하나은행은 불확실한 경제 상황 속에서도 장기신용등급은 ‘A’, 등급전망은 ‘안정적’으로 유지한 가운데 독자신용등급(VR, Viability Rating)의 한 단계 상향을 이뤄내며 그간의 ...
서울안심소득
재택치료_상담_진료방법안내
모바일 버전 바로가기